Did You Know...
...that Kleenex tissue was originally designed to be a gas mask filter? It was developed at the beginning of World War I to replace cotton, which was then in short supply as a surgical dressing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188045 | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with periopera... | 05/29/2012 |
| 8163717 | Dual chain synthetic heparin-binding growth factor analogs The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, whic... | 04/24/2012 |
| 8088753 | Heparin conjugates and methods Heparin conjugates and methods of making and use thereof are disclosed. An illustrative heparin conjugate includes a composition wherein a bile acid is bonded to heparin through the 3-carbon of the bile acid. A spacer may be interposed between the bile acid and the ... | 01/03/2012 |
| 8071570 | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them. ... | 12/06/2011 |
| 8071569 | Oxidized heparin fractions and their use in inhibiting angiogenesis The present invention relates to a heparin fraction comprising constituents having molecular weights of from about 2,000 to about 4,000 daltons, wherein from about 1% to about 100% of hydroxyl residues of the constituents are oxidized. The present invention also rel... | 12/06/2011 |
| 8026209 | Methods and compositions for targeting agents into and across the blood-barrier and other endothelial cell microvascular barriers The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are ... | 09/27/2011 |
| 8003623 | Mixtures of sulfated oligosaccharides The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them. ... | 08/23/2011 |
| 7981873 | Use within transplantation surgery The present invention is within the field of transplantation surgery. More closely, the present invention relates to use of a clotting preventing agent in the production of a drug for administration in association with transplantation of insulin producing cells in t... | 07/19/2011 |
| 7968527 | Inhibition of FGF signaling Methods and compositions for inhibiting FGF signaling are described. Methods of the invention include contacting an FGF-responsive cell with exogenous heparan sulfate 6-O endosulfatase (Sulf1) in an amount effective to modify endogenous heparan sulfate, thereby inhi... | 06/28/2011 |
| 7939512 | Multistep process for the physical depolymerization of heparin and products obtained therefrom The present invention is directed to a multistep process for the physical depolymerization of heparin wherein heparin is subjected to at least two γ-ray irradiations and wherein between two irradiation steps the depolymerised heparin is subjected to a separation st... | 05/10/2011 |
| 7928089 | Mucoactive agents for treating a pulmonary disease The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention ... | 04/19/2011 |
| 7875596 | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/... | 01/25/2011 |
| 7812007 | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them Alkali and alkali-earth metal salts of polysaccharides derived from heparin, their method of preparation and the pharmaceutical compositions containing them. ... | 10/12/2010 |
| 7790700 | Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect Partially desulfated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. The... | 09/07/2010 |
| 7737130 | Pharmaceutical compositions for topical use in treatment of skin or mucous injuries The present invention describes new pharmaceutical compositions in treatment of skin and/or mucous injuries, new therapeutic use of compounds and use of compositions and compounds in treatment of injuries that involve skin and/or mucous, and/or therapies where regen... | 06/15/2010 |
| 7737131 | Multifunctional and biologically active matrices from multicomponent polymeric solutions The present invention relates to a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of biologically active agents. In particular the invention relates to a functionalized polymer matrix comprising a matrix polymer... | 06/15/2010 |
| 7732427 | Multifunctional and biologically active matrices from multicomponent polymeric solutions The present invention relates to a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of biologically active agents. In particular the invention relates to a functionalized polymer matrix comprising a matrix polymer... | 06/08/2010 |
| 7696182 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition compris... | 04/13/2010 |
| 7687479 | Methods and producing low molecular weight heparin The invention relates, in part, to methods and products related to producing low molecular weight heparin. ... | 03/30/2010 |
| 7563780 | Heparin prodrugs and drug delivery stents formed therefrom A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a... | 07/21/2009 |
| 7560444 | Polysaccharides for pulmonary delivery of active agents Formulation for pulmonary delivery of a therapeutic, prophylactic, or diagnostic agent including a low molecular weight heparin and a therapeutic, prophylactic, or diagnostic agent. ... | 07/14/2009 |
| 7550444 | Composition and method for preparing biocompatible surfaces The invention provides methods and compositions for providing biocompatible surfaces to medical articles. In particular the invention provides biocompatible coatings with heparin activity. In some aspects, the biocompatible coatings of the invention are able to rele... | 06/23/2009 |
| 7550443 | Process and systems for biocompatible surfaces The invention provides methods and compositions for providing biocompatible surfaces to medical articles. In particular the invention provides biocompatible coatings with heparin activity that are able to release a bioactive agent, wherein the coatings are formed us... | 06/23/2009 |
| 7538096 | Treatment and prevention of abnormal cellular proliferation This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of O-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regul... | 05/26/2009 |
| 7468358 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin-and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccha... | 12/23/2008 |
| 7407945 | Use of sulfated glycosaminoglycans for establishing effective labor in women The invention refers to the use of sulfated glycosaminoglycans having an anticoagulant activity of 100 BP units/mg or less for the manufacture of a pharmaceutical preparation for prophylactic priming or curative treatment of the cervix and the myometrium for establi... | 08/05/2008 |
| 7399604 | Methods and products related to evaluating the quality of a polysaccharide The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminogly... | 07/15/2008 |
| 7393840 | Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one he... | 07/01/2008 |
| 7361644 | Specific antagonist for both E- and P-selectins Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-med... | 04/22/2008 |
| 7335334 | Active air removal from an extracorporeal blood circuit A disposable, integrated extracorporeal blood circuit employed during cardiopulmonary bypass surgery performs gas exchange, heat transfer, and microemboli filtering functions in a way as to conserve volume, to reduce setup and change out times, to eliminate a venous... | 02/26/2008 |
| 7335391 | Method for coating implantable devices A method of forming a coating for an implantable medical device, such as a stent, is provided which includes applying a composition to the device in an environment having a selected pressure. ... | 02/26/2008 |
| 7332480 | Compositions for the regulation of cytokine activity Substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, including compositions containing same and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of Tumo... | 02/19/2008 |
| 7332227 | Non-volatile lubricant system for medical devices A non-volatile lubricious coating composition is provided for use with medical devices, such as hypodermic needles, catheters, and the like. The coating composition includes a first siloxane polymer having a very low viscosity less than about 50 centistokes, a secon... | 02/19/2008 |
| 7329413 | Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof Coatings for implantable medical devices, and methods for fabricating thereof, are provided. The coatings include a first polymer layer and a second polymer layer, where the second polymer has a higher degree of hydration than the first polymer. ... | 02/12/2008 |
| 7318932 | Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same A polymer coating for medical devices based on a derivatized poly(ethylene-co-vinyl alcohol) is disclosed. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include poly(ethylene-co-vinyl a... | 01/15/2008 |
| 7311980 | Polyactive/polylactic acid coatings for an implantable device A polymeric coating for a medical device that comprises poly(lactic acid) and a block copolymer including blocks of poly(ethylene glycol) and poly(butylene terephthalate) is provided. ... | 12/25/2007 |
| 7303768 | Preparation of aqueous clear solution dosage forms with bile acids Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the inve... | 12/04/2007 |
| 7297343 | Bioactive medical films A wound dressing, method of making, and method of use, utilizing a polymeric film having complexed thereto by hydrophobic interaction a construct including a polyanion covalently bonded to a hydrophobic prosthetic moiety, with one or more bioactive molecules directl... | 11/20/2007 |
| 7294357 | Plasma coated sutures Suture filaments coated by a plasma polymerization process exhibit a good balance of knot run down and knot security characteristics, superior tissue drag characteristics, and improved fray resistance. ... | 11/13/2007 |
| 7291639 | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) This invention provides methods of inhibiting plasminogen activator inhibitor-1 (PAI-1) in a mammal, utilizing compounds of the formula: wherein: A is C or N; B is O, S, N, or CH═CH; | 11/06/2007 |
